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INTRODUCTION
6 in the acute stage parasite burden, induction of a favourable cytokine profile, and reduction in 138 disease pathology. However, detailed analysis of vaccine efficacy has been limited by an 139 inability to accurately monitor parasite levels during the chronic stage and technical difficulties 140 in assessing the effect of the immune response on tissue distribution following challenge 141 infections. 142
143
Recently, in vivo imaging approaches have been exploited to provide new insights into 144 infection dynamics during experimental chronic Chagas disease (24, 25, 36) . These studies 145 have revealed the pantropic nature of acute stage infections, and shown that during the 146 chronic stage, the adaptive immune response restricts parasites to small infection foci, 147 predominantly within the GI tract. Other tissues and organs, including the heart and skeletal 148 muscle, are infected sporadically, the extent of which is influenced by host:parasite genetics 149 and immune status. Additional factors such as nutrition, environmental stimuli, age and co-150 infections could also play a role in this complex chronic infection profile (37). The survival of 151 the small parasite foci within apparently tolerant sites is crucial for long-term infection, although 152 the immunological context of these reservoirs is unknown. Another contributor to the long-term 153 nature of T. cruzi infections could be the phenomenon of parasite dormancy; individual 154 intracellular amastigotes can enter an apparently quiescent state in which they cease to 155 replicate and exhibit reduced drug sensitivity (38) . Neither the mechanisms involved, nor the 156 potential implications for immune evasion have yet been established. 157 158 Highly sensitive bioluminescence imaging involves the use of T. cruzi strains that have been 159 modified to express a red-shifted luciferase reporter (39). The system allows the real-time 160 monitoring of parasite burden in experimental mice during chronic stage infections. There is a 161 robust correlation between parasite numbers and whole animal bioluminescence, with a limit 162 of detection close to 100 parasites (24). Here, we describe the use of this imaging technology 163 to assess the extent of protection in benznidazole-cured mice following re-challenge with 
Drug treatment and immunosuppression 249
Benznidazole was synthesized by Epichem Pty Ltd., Australia, and prepared at 10 mg ml −1 in 250 an aqueous suspension vehicle containing 5% (v/v DMSO, 0.5% (w/v) hydroxypropyl 251 methylcellulose, 0.5% (v/v) benzyl alcohol and 0.4% (v/v) Tween 80. It was administered by 252 oral gavage. To detect any residual infection following treatment, mice were 253 immunosuppressed with cyclophosphamide monohydrate (Sigma) in D-PBS (200 mg kg −1 ), 254 administered by i.p. injection every 4 days, for 3 doses. Two weeks after the end of 255 immunosuppression, mice that were bioluminescence negative by both in vivo and ex vivo 256 imaging were designated as cured. 
Monitoring ASP-2/TS vaccine efficacy using highly sensitive bioluminescence imaging 278
The T. cruzi amastigote surface protein 2 (ASP-2) and trypomastigote cell surface protein 279 trans-sialidase (TS) have shown promise as vaccine candidates against T. cruzi infections 280 (44-46). To further assess their efficacy, we used two replication-deficient recombinant 281 vaccine platforms, a chimpanzee adenovirus (ChAdOx1) and a Modified Vaccinia Ankara virus 282 (MVA), expressing ASP-2 and TS peptides from a single open reading frame ( Fig 1A) 283
(Materials and Methods) (40). We used a homologous prime-boost vaccination strategy in 284 which BALB/c mice received intramuscular injections administered one week apart ( Fig 1B) 285 and confirmed immunogenicity of the vaccine delivery system using an ex vivo IFN-γ + ELISpot. 286
Three weeks after receiving either a prime only, or a prime-booster vaccination, splenocytes 287 were plated on antibody coated ELISpot plates. When these cells were then stimulated with a 288 peptide pool representing the entire ASP-2/TS sequence, there was a pronounced increase 289 in the number of peptide specific IFN-γ + splenocytes, particularly in those mice that had 290 received the booster ( Fig 1C) . To test protective efficacy, mice were vaccinated using the homologous prime-boost strategy 304 outlined above. Three weeks after the MVA booster, they were challenged by i.p. injection with 305 12 infection was monitored by in vivo imaging (36) (Materials and Methods). In BALB/c mice, 307 parasites rapidly disseminate and proliferate, with the infection reaching a peak after 308 approximately 2 weeks. Thereafter, a vigorous adaptive immune response reduces the 309 parasite burden by >2 orders of magnitude, and the infection transitions to the life-long chronic 310 stage (24). No differences were observed in the bioluminescence-inferred parasite burden 311 between vaccinated and control mice at the earliest time-point assessed (day 7, post-infection) 312
(Figs 2B and C). However, by day 15, the peak of the acute stage, the ASP-2/TS vaccinated 313 mice displayed a 77% reduction in the bioluminescence-inferred parasite burden. This 314 protective effect was maintained until day 21. By day 28, against a background of immune-315 mediated reduction in the parasite burden, there were no significant differences between the 316 vaccinated and control groups. From that point onwards, the parasite burden remained similar 317 between the groups (Figs 2B and C). Following termination of the experiment (day 95), ex vivo 318 imaging of internal organs and tissues revealed that the profile of infection in the vaccinated 319 cohort was typical of the chronic stage. The colon and/or stomach were the major tissues 320 persistently parasitized, with infections in other organs being sporadic. There were no 321 apparent differences in the tissue-specific parasite burden between vaccinated and control 322 mice ( Fig 2D) . Therefore, although vaccination with the ASP-2/TS constructs can reduce 323 parasite burden during the acute stage, it does not impact on the long term burden of chronic 324 infections. To place the recombinant vaccine results into context, we sought to establish the extent to 341 which drug-cured infections could enhance the capacity of the murine immune response to 342 protect against challenge. BALB/C mice were first inoculated i.p. with bioluminescent parasites 343 (CL Brener strain) (n=12). At three different points post-infection (4, 14 and 36 days) ( Fig 3A) , 344
we initiated treatment with benznidazole (100 mg kg -1 ), once daily, for 20 consecutive days. 345
This dosing regimen was shown to be curative ( Supplementary Fig 1) , in line with previous 346 results (47, 48). The plasma concentration of benznidazole falls below the in vitro EC50 value 347 in approximately 12 h (48) . 21 days after the cessation of treatment, the cured mice were re-348 infected i.p. and monitored regularly by in vivo imaging ( Fig 3B and C) . 70 days after challenge, 349 mice found to be bioluminescence-negative were immunosuppressed to facilitate the Representative ex vivo bioluminescence images. Upper inset, organs from control mouse 70 367 days post-infection. Central inset, organs from a mouse that was re-infected following curative 368 treatment initiated on day 36 of the primary infection. On day 70 of the challenge infection, 369
immunosuppressive treatment was initiated and the organs then harvested. In this instance, 370 a residual infection was identified. Lower inset, organs from a mouse treated as above, which 371 was non-infected after challenge. 372
373
When curative treatment was initiated at 36 days post-infection, none of the mice exhibited a 374 distinct acute stage infection peak following challenge (Figs 3B and C). There was >99% 375 reduction in the inferred parasite burden in all cases, compared to primary infection control 376 mice. At the experimental end-point, 6 out of 12 mice were shown to be fully protected (Table  377 1, Fig 3D, Supplementary Fig 2) . In cases where the primary infection was allowed to proceed 378 for 14 days prior to the initiation of curative benznidazole treatment, the infection profile 379
following challenge was very similar to the cohort where treatment was initiated 36 days post-380 infection. However, a greater number of foci were detectable during the period corresponding 381 to the acute stage of primary infections ( Fig 3B) , with full protection achieved in 3 out of 12 382 mice. In contrast to both of the above, when curative treatment began 4 days after the primary 383 infection, there was a clear acute stage peak in the bioluminescence profile following 384 challenge ( Fig 3C) . The kinetic profile mirrored that in control infected mice, although the 385 maximum parasite burden was 85% lower, and sterile protection was restricted to a single 386 mouse (Table 1) . Therefore, although the immune response induced by a short course 387 infection is able to impact on the burden of re-infection, the effect is significantly limited 388 compared with what is achievable when the primary infection is allowed to progress fully into 389 the acute stage, prior to treatment. To assess whether this protective effect was dependent on the route of inoculation, we 407 repeated the 36 day challenge experiment using the subcutaneous (s.c.) route. T. cruzi 408 transmission normally occurs when parasite-infected faeces from the insect vector are rubbed 409 into the wound produced by blood feeding; therefore, s.c. inoculation probably reflects more 410 closely how the majority of human infections occur. The mice were inoculated s.c. with 10 3 411 bloodstream trypomastigotes for both the primary and challenge infections, but the protocols 412 and treatment timelines were otherwise identical to those used previously ( Fig 3A, 36 imaging ( Fig 4A) , none of the mice displayed an acute stage peak, and bioluminescence was 417 at, or close to background levels. At the experimental end-point, all of the mice were 418 immunosuppressed and then subjected to post-mortem ex vivo organ imaging to test for foci 419 of infection below the limit of in vivo detection. 4 out of 5 were found to be bioluminescence 420 negative in all analyses and were designated as protected (Table 1) . imaging of organs and carcass of a control and the re-infected mouse that was found to be 435 non-protected after immunosuppression. (G) As above, BALB/c mice were infected i.p. and 436 subjected to curative benznidazole treatment. 338 days after the end of treatment, they were 437 re-infected (i.p.) with 10 3 trypomastigotes. (H) Total body bioluminescence of drug-cured mice 438
following re-infection. The increased mean bioluminescence of the re-infected mice towards 439 the end of the monitoring period was due to an intense bioluminescence focus in one of the 440 two non-protected animals. (I) Ex vivo bioluminescence imaging of organs and carcass of a 441 control and a re-infected mouse that was found to be non-protected after immunosuppression. 442
In all cases, the original cohort size was n=6. During the course of the s.c. infection experiment 443
(A-C), one mouse failed to recover from anaesthesia, and was excluded from the analysis. 444
445
It has been reported that the capacity of a cured mouse to resist re-infection is dependent on 446 the size of the challenge inoculum (49). To investigate this using the in vivo imaging system, 447 mice where curative treatment was initiated 36 days post infection were challenged i.p. with 448 6x10 4 CL Brener trypomastigotes, 60 times the number used previously. The outcome was 449 similar. None of the mice displayed an acute stage parasite burden profile, and only a single 450 mouse (out of 6) was non-protected ( Fig 4D, E and F) . Therefore, the level of protection 451 conferred by a cured infection is similar when a higher challenge inoculum is used. 452
453
We next sought to determine whether protection results from the development of 454 immunological memory, rather than retention of effector cells from the primary infection. 455 BALB/c mice were infected i.p. with CL Brener trypomastigotes, and curative benznidazole 456 treatment was initiated after 36 days. On this occasion, however, the mice were not re-infected 457 until 338 days after the cessation of treatment. Following homologous challenge, the level of 458 protection was comparable to that achieved in previous experiments when mice were re-459 infected 3 weeks after the last dose of benznidazole. They were able to prevent the onset of 460 parasite proliferation during the acute stage, and 4 out of 6 mice were fully protected (Figs 4G, 461 H, and I). 462 463
Assessing circulating IFN-γ + T cells in mice after primary infection and challenge 464
We sought to determine if the duration of the primary infection, prior to commencement of 465 curative drug treatment, impacted on the extent of the T. cruzi-specific immune response to 466 challenge with homologous parasites. Blood was collected, 2 days prior to re-infection and at 467 regular intervals thereafter, from mice that had been infected for 4, 14 and 36 days ( Fig 5A) . 468
PBMCs were isolated, re-stimulated with an ASP-2 and TS peptide pool, and the IFN-γ + cell 469 frequencies measured by ELISpot (Materials and Methods). As expected for mice infected 470 with T. cruzi (50), the control group receiving their first parasite exposure showed a delayed 471 peptide-specific response, with the frequency of IFN-γ + cells on day 10 not significantly 472 different to pre-infection levels. There were substantial increases by days 25 and 40 ( Fig 5B) , 473 co-incident with the period when the parasite burden had been controlled and was undergoing 474 major reduction (Figs 3B and C) . T cells varied, depending on the duration of the preliminary infection ( Fig 5B) . Initially, mice 488 that had been infected for 36 days prior to cure displayed higher levels than the control cohort 489 (day -2). However, these levels did not increase significantly following re-infection, although 490 in the case of the day 14 group, there was a slight trend in this direction. In the control group, 491 the robust adaptive response, which controlled the infection, was associated with levels of 492 circulating IFN-γ + T cells that were significantly higher than in any of the benznidazole-cured 493 mice by 40 days post-challenge ( Fig 5B) . Mice that had been infected for only 4 days prior to 494 drug-cure, displayed IFN-γ + T cell kinetics that were initially more similar to naïve mice 495 receiving their preliminary infection, with very low levels before and 10 days post-challenge, 496 followed by a major increase by day 25. The levels decreased thereafter, in contrast to the 497 control group, where they continued at higher levels until day 40. 498
499
We also examined circulating parasite-specific IFN-γ + T cells in mice that had been re-infected 500 338 days after drug cure ( Fig 6A) . Prior to re-challenge, the levels were similar to those in non-501 infected control mice. However, by 10 days post-challenge, there had been a 5-fold increase, 502 in contrast to the delayed peptide-specific response typical of a T. cruzi infection ( Fig 6B) . This 503 difference was not maintained, and on days 25 and 40 after challenge, the level of IFN-γ + T 504 cells was not significantly different from control mice. 
The capacity of drug-cured infections to confer a cross-strain protective response 515
T. cruzi displays significant genetic diversity, with the natural population subdivided into 6 516 lineages known as discrete typing units (DTUs), each of which has the ability to infect humans 517 (51). We therefore investigated if the capacity to confer homologous protection is a general 518 feature of T. cruzi infections by performing an analogous experiment using JR strain parasites 519 from the genetically distant TcI lineage). In BALB/c mice, infections with this strain are slightly 520 slower to reach the peak of the acute stage, but the bioluminescence profile is otherwise 521 similar to that of the CL Brener strain (DTU VI lineage) (25). Mice were benznidazole-treated 522 36 days into a JR infection, and re-infected with the same strain 20 days after the end of 523 treatment ( Fig 7A) . As before, we observed that the cured infection conferred significant 524 protection. None of the mice exhibited a distinct acute stage peak, with the majority remaining 525 close to bioluminescence background levels ( Figs 7B and C) . However, only a single mouse 526 (out of 6) exhibited sterile protection when assessed by ex vivo imaging following 527 immunosuppression (Materials and Methods) ( Fig 7D) . To assess the scope for vaccine-induced species-wide immunity, we next investigated the 549 effectiveness of protection conferred against a heterologous challenge using the strains CL 550 Brener (TcVI) and JR (TcI). Following the strategy outlined above, BALB/c mice were infected 551 i.p. with 10 3 bloodstream CL Brener or JR trypomastigotes, benznidazole-treated, and then 552 challenged with the heterologous strain 20 days after the end of the curative therapy. In both 553 experiments, we observed a strong protective response (>99%) (Figs 7E-J), with no distinct 554 acute stage peak and a reduced number of bioluminescent foci in the period corresponding to 555 the transition to the chronic stage. However, in both cases, all mice exposed to cross-strain 556 challenge displayed small but clear parasite foci following re-infection. None exhibited sterile 557 protection when examined by ex vivo imaging, with each displaying the type of GI tract 558 infections characteristic of the chronic stage (Figs 7G and J). Therefore, although infection 559 with a heterologous strain can have a major impact on the subsequent parasite burden, it did 560 not confer sterile immunity in any of the mice examined. Despite this, there have been an increasing number of reports that vaccination could have 571 therapeutic benefits in terms of decreased cardiac pathology (33, (52) (53) (54) . Therefore, the 572 question as to whether the development of a Chagas disease vaccine might be a practical 573 option for reducing the public health impact of this infection remains unanswered. Detailed 574 assessment has been limited by difficulties in detecting the intermittent low-level parasitemia 575 of chronic stage infections, and in identifying the tissue/organ location of persistent parasites. 576
Here, we demonstrate that highly sensitive bioluminescent imaging can negate some of these 577 issues, and provide novel insights into vaccine efficacy. 578 579 Initially, we tested the protective properties of two viral vectors (MVA and ChAdOx1) that had 580 been modified to express an ASP-2/TS fusion gene (Fig 1) . The reduction in peak parasite 581 burden (77%, Fig 2C) was in a range similar to that reported for other recombinant T. cruzi 582 vaccines (55-57, as examples). Interestingly, vaccination had no impact on the parasite 583 burden once the infection had transitioned to the chronic phase, suggesting that if parasites 584 can survive until this stage of the disease, they are less susceptible to clearance by vaccine-585 induced immunity. This has not been reported previously. At the experimental end-point, the 586 remaining parasites were restricted predominantly to the GI tract ( Fig 2D) . In BALB/c and other 587 mice, this location serves as a permissive niche, enabling parasites to persist in an otherwise 588 hostile immune environment (24, 25, 37), although the mechanism(s) for this have yet to be 589 elucidated. To determine if this might limit the utility of a Chagas disease vaccine, we therefore 590 investigated the protective effect of benznidazole-cured infections, on the basis that these 591 should provide optimal levels of immunity. Curative treatment has been associated with the 592 development of a stable anti-T. cruzi CD8 + T cell population (22) . 593
22
Drug-cure was initiated after infection for 36 days (a time-point when the adaptive CD8 + T cell 595 response is controlling the infection), 14 days (the peak of the acute stage), and 4 days (just 596 short of one complete round of the intracellular replication cycle that leads to differentiation 597 and parasite egress) (Fig 3) . Mice infected for 36 days prior to benznidazole treatment were 598 highly protected from challenge ( Fig 3B) , with complete absence of a typical acute stage peak. 599
However, sterile protection was only achieved in half of the re-infected mice ( Table 1) . 600
Therefore, although drug-cured infections can generate a highly effective immune response, 601 that prevents a second acute phase, parasites that evade this initial encounter seem to be 602 refractory to immune-mediated elimination and are able to persist long term. This outcome 603 was not significantly influenced by the size of the challenge inoculum or the route of infection 604 (Fig 4) . Initiating treatment after 14 days was also able to prevent a detectable acute stage 605 peak in bioluminescence when the mice were challenged, although there was a slight 606 reduction in the level of sterile protection ( Fig 3B, Table 1 ). In contrast, when drug-cure was 607 initiated after 4 days, a pronounced post-challenge acute stage peak could be observed, but 608 even then, the parasite burden was 85% lower than in a naive infection. Therefore, 14 days 609 exposure to an untreated infection is sufficient for the induction of a robust immune response, 610
whereas with 4 days, the response appears to be less developed, although still sufficient to 611 have a significant impact on the parasite burden. 612 613 A delayed onset of the CD8 + T cell response is a characteristic feature of Chagas disease 614 (58), with the first round of intracellular infections passing largely undetected by the immune 615 system. Upon invasion of mammalian cells, parasites rapidly escape from the phagolysosome, 616 there is down-modulation of the host cell immunoproteasome (59), and minimal activation of 617 the host-pattern recognition receptors. Induction of effective innate immunity requires a full 618 cycle of parasite replication, host cell lysis, and the release of trypomastigotes into the 619 extracellular milieu, a process that takes at least 4-5 days. This is followed by the production 620 of pathogen-associated and damage-associated molecular patterns that promote innate 621 immune responses, allowing parasitized cells to flag up their infected status by MHC class I 622 23 antigen presentation. Full development of the CD8 + T cell response to T. cruzi infections takes 623 around 3 weeks (58). In mice where curative treatment was initiated 14 or 36 days post-624 infection, circulating parasite peptide-specific IFN-γ + T cells were readily detectable prior to 625 challenge ( Fig 5B) , and were associated with protection against the development of a second 626 acute phase profile. In many cases, this response was sufficient to promote complete 627 elimination of the secondary infection. Experimental challenge did not lead to a significant 628 increase in the level of IFN-γ + T cells, suggesting that the pre-existing effector population was 629 able to contain the secondary infection without further induction. Even when preliminary 630 infection did not confer sterile protection, there was no further enhancement of the peptide-631 specific response. Therefore, if parasites in the challenge inoculation can avoid early 632 elimination, and are able to establish a long term chronic infection, it appears that they survive 633 in an environment or state that does not trigger additional T cell activation. 634
635
In mice where curative treatment was initiated 4 days into the primary infection, the level of T. 636 cruzi-specific IFN-γ + T cells prior to re-infection was negligible, and the kinetics of the response 637 induced over the first 25 days of the challenge infection was similar to that in the controls (Fig  638   5 ). Despite this, there was an 85% reduction in the parasite burden at the peak of the re-639 infection. Therefore, the induced partially protective effect in these mice is conferred either by 640 an extremely low level of circulating parasite-specific IFN-γ + T cells, or by other factors that 641 operate to moderate the infection. In mice challenged almost a year after curative treatment 642 of the primary infection, the level of protection was similar to mice in which the gap between 643 the end of treatment and challenge was only ~20 days. However, unlike these mice, re-644 infection after almost a year was accompanied by induction of peptide-specific T cells, with 645 kinetics that were more rapid than in the naive control cohort (Fig 6) . This evidence for a 646 memory response suggests that vaccine-mediated long term protection against fulminant T. 647 cruzi infection may be a feasible goal. Furthermore, if these results can be extrapolated to 648 humans, it would imply that patients who have undergone curative drug treatment should have 649 the added benefit of a high level of long term protection against re-infection. 650
